# Hemiasterlin payloads

Source: https://onco.cc/terms/hemiasterlin-payloads/  
OnCo record `hemiasterlin-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hemiasterlin-derived payloads disrupt the scaffolding used in cell division. One is carried by the experimental antibody drug luveltamab tazevibulin.

## Summary

Luveltamab tazevibulin, or STRO-002, uses the folate receptor alpha antibody to deliver the tubulin-targeting hemiasterlin derivative SC209. SC239 is the linker-warhead used to assemble the conjugate, not a synonym for the released SC209 alone. The primary discovery study reported antigen-dependent killing, bystander activity and efficacy in xenograft models. This is a different scaffold within the tubulin class, not a mechanism unrelated to tubulin.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: SC209; tazevibulin payload; 3-aminophenyl hemiasterlin; SC239 linker-payload

## Sources

- Discovery of STRO-002 and its hemiasterlin payload (2023): https://doi.org/10.1158/1535-7163.MCT-22-0322

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Luveltamab tazevibulin](https://onco.cc/drugs/luveltamab-tazevibulin/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)

---
JSON: https://onco.cc/api/v1/entities/hemiasterlin-payloads.json